Abstract
Acromegaly is a rare systemic disease, predominantly caused by growth hormone (GH)-secreting pituitary adenoma, leading to insulin-like growth factor-1 (IGF-1) overproduction. Pituitary adenoma extension and/or its treatment can cause infertility or subfertility in both sexes in different mechanisms. Pregnancies in women with active acromegaly are rarely observed but considered generally safe. Growth hormone and IGF-1 concentrations are usually stable during pregnancy and in most cases no significant tumour expansion emerges despite pharmacological therapy withdrawal.
A 28 year-old woman with symptoms of acromegaly and amenorrhoea was admitted to the Department of Endocrinology. Diagnosis of acromegaly was made and treatment with somatostatin analogues (SSA) was initiated with subsequent surgical intervention. However, persistent acromegaly was diagnosed post-operatively due to residual tumour and the medical treatment was restarted. During follow-up the patient became pregnant twice and then treatment with somatostatin analogues was ceased. Both pregnancies were complicated by gestational diabetes and in the course of the second pregnancy treatment with dopamine agonist (DA) was commenced to alleviate persistent headaches and it was followed by clinical and biochemical improvement. The patient successfully delivered two healthy babies. After second labour treatment with SSA was resumed and the patient has achieved adequate disease control.
The risk of pregnancy complications in women with acromegaly is slightly higher than in general population, especially if uncontrolled disease was present before conception or acromegaly was diagnosed during pregnancy. In rare cases pituitary tumour expansion during pregnancy occurs and then pharmacological or surgical interventions should be considered.
References
(1) Bolanowski M, Ruchała M, Zgliczyński W, et al. Diagnostics and treatment of acromegaly – updated recommendations of the Polish Society of Endocrinology. Endokrynol Pol 2019; 70(1):2-18. DOI:10.5603/EP.a2018.0093.
(2) Grynberg M, Salenave S, Young J, et al.: Female gonadal function before and after treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010; 95:4518-4525. DOI:10.1210/jc.2009-2815.
(3) Caron P, Broussaud S, Bertherat J, et al.: Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. Journal of Clinical Endocrinology and Metabolism 2010; 95:4680-4687. DOI:10.1210/jc.2009-2331.
(4) Cheng V, Faiman C, Kennedy L, et al.: Pregnancy and acromegaly: a review. Pituitary 2012; 15:59-63. DOI:10.1007/s11102-011-0330-3.
(5) Jallad RS, Shimon I, Fraenkel M, et al.: Outcome of pregnancies in a large cohort of women with acromegaly. Clinical Endocrinology 2018; 88:896-907. DOI:10.1111/cen.13599.
(6) Hannon A, O’Shea T, Thompson C, et al.: Pregnancy in acromegaly is safe and is associated with improvements in IGF-1 concentrations. European Journal of Endocrinology 2019; 180(4):21-29. DOI:10.1530/EJE-18-0688.
(7) Abucham J, Bronstein MD, Dias ML. Management of Endocrine Disease: Acromegaly and pregnancy: a contemporary review. European Journal of Endocrinology 2017; 177(1):1-12. DOI:10.1530/EJE-16-1059.
(8) Assal A, Malcolm J, Lochnan H, et al.: Preconception counselling for women with acromegaly: More questions than answers. Obstet Med 2016; 9(1):9-14. DOI:10.1177/1753495X15598699.
(9) Dias M, Boguszewski C, Gadelha M, et al.: Acromegaly and pregnancy: a prospective study. European Journal of Endocrinology 2014; 170:303-312. DOI:10.1530/EJE-13-0460.
(10) Cheng S, Grasso L, Martinez-Orozco JA, et al.: Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clinical Endocrinology 2012; 76(2):264-271. DOI:10.1111/j.1365-2265.2011.04180.x
(11) Persechini ML, Gennero I, Grunenwald S, et al. Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function. Pituitary 2015 Aug; 18(4):461-4. DOI:10.1007/s11102-014-0596-3.
(12) Muhammad A, Neggers SJ, van der Lely AJ. Pregnancy and acromegaly. Pituitary 2017 Feb; 20(1):179-184. DOI:10.1007/s11102-016-0740-3.
(13) Yen SS. Endocrine – metabolic adaptations in pregnancy. In: Reproductive Endocrinology: Physiology Pathophysiology and Clinical Management. Eds Yen SSC, Jaffe RB & Barbieri RL. Philadelphia: WB Saunders Company 1991.
(14) Yang MJ, Tseng JY, Chen CY, et al.: Changes in maternal serum insulin-like growth factor-I during pregnancy and its relationship to maternal anthropometry. Journal of the Chinese Medical Association 2013; 76: 635-639. DOI:10.1016/j.jcma.2013.07.004.
(15) Katznelson L, Laws ER, Melmed S, et al.: Acromegaly: an Endocrine Society Clinical Practice guideline. Journal of Clinical Endocrinology and Metabolism 2014; 99:3933-3951. DOI:10.1210/jc.2014-2700.
(16) Gonzalez JG, Elizondo G, Saldivar D, et al.: Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. American Journal of Medicine 1988; 85(2):217-220. DOI:10.1016/S0002-9343(88)80346-2.
(17) Dinç H, Esen F, Demirci A, et al. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 1998 Jan; 39(1):64-9.
(18) Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Annals of internal medicine 1994; 12:1473-477. DOI:10.7326/0003-4819-121-7 -199410010-00001.
(19) Kasuki L, Neto LV, Takiya CM, et al. Growth of an aggressive tumor during pregnancy in an acromegalic patient. Endocr J 2012; 59(4):313-9. Epub 2012 Jan 12.
(20) Hannon AM, Frizelle I, Kaar G, et al. Octreotide use for rescue of vision in a pregnant patient with acromegaly. Endocrinol Diabetes Metab Case Rep. 2019 May 20; 2019. DOI:10.1530/EDM-19-0019.
(21) Chanson P, Vialon M, Caron P. An update on clinical care for pregnant women with acromegaly. Expert Rev Endocrinol Metab 2019 Mar; 14(2):85-96. DOI:10.1080/17446651.2019.1571909. Epub 2019 Jan 30.
(22) Haliloglu O, Dogangun B, Ozcabi B, et al.: General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers. Pituitary 2016; 19:391-398. DOI:10.1007/s11102-016-0717-2.
(23) Kintiraki E, Papakatsika S, Kotronis G, et al.: Pregnancy-induced hypertension. Hormones 2015; 14:211-223. DOI:10.14310/horm.2002.1582.
(24) Mozas J, Ocon E, Lopez de la Torre M, et al.: Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection. International Journal of Gynaecology and Obstetrics 1999; 65:71-73. DOI:10.1016/S0020-7292(98)00221-5.
(25) de Menis E, Billeci D, Marton E, et al.: Uneventful pregnancy in an acromegalic patient treated with slow-release lanreotide: a case report. Journal of Clinical Endocrinology and Metabolism 1999; 84:1489. DOI:10.1210/jcem.84.4.5625-5.
(26) Takano T, Saito J, Soyama A, et al.: Normal delivery following an uneventful pregnancy in a Japanese acromegalic patient after discontinuation of octreotide long acting release formulation at an early phase of pregnancy. Endocrine Journal 2006; 53:209-212. DOI:10.1507/endocrj.53.209.
(27) Maffei P, Tamagno G, Nardelli GB, et al.: Effects of octreotide exposure during pregnancy in acromegaly. Clinical Endocrinology 2010; 72:668-677. DOI:10.1111/j.1365-2265. 2009.03706.x.
(28) Ricci E, Parazzini F, Motta T, et al.: Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology 2002; 16:791-793. DOI:10.1016/S0890-6238(02)00055-2.
(29) Colao A, Abs R, Barcena DG, et al.: Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clinical Endocrinology 2008; 68:66-71. DOI:10.1111/j.1365-2265.2007.03000.x.
(30) Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. European Journal of Endocrinology 2015; 172:205-213. DOI:10.1530/EJE-14-0848.
(31) van der Lely AJ, Gomez R, Heissler JF, et al. Pregnancy in acromegaly patients treated with pegvisomant. Endocrine 2015; 49:769-773. DOI:10.1007/s12020-014-0508-3.
This work is licensed under a Creative Commons Attribution 4.0 International License.